• ABT-737: BCL-2 Protein Inhibitor Workflows

  2026-09-17

  ABT-737 provides a practical way to test mitochondrial apoptosis dependence across lymphoma, multiple myeloma, small-cell lung cancer, and AML models. This workflow connects concentration–response experiments with endogenous BAX/BAK imaging, helping distinguish genuine pathway activation from assay or overexpression artifacts.

• ABT-263 (Navitoclax) Apoptosis Workflows

  2026-09-17

  ABT-263 (Navitoclax) converts Bcl-2 family dependence into a practical experimental variable for apoptosis, senescence, and cancer biology studies. This guide shows how to pair dose-response testing with real-time imaging, mitochondrial priming, and caspase readouts to distinguish true senolytic sensitivity from nonspecific toxicity.

• ABT-263 (Navitoclax) Apoptosis Workflow

  2026-09-16

  ABT-263 (Navitoclax) converts Bcl-2 family dependence into a measurable experimental variable for apoptosis, mitochondrial priming, and cancer biology studies. This guide connects dose-response design with orthogonal cell-death readouts and the emerging insight that Pol II degradation can activate death independently of transcriptional loss.

• 2'-O-Methyladenosine: From Metabolite to Mechanism

  2026-09-16

  A translational framework for using 2'-O-Methyladenosine to connect RNA modification biology, purine metabolism studies, quantitative mass spectrometry, and decision-ready cell-based research.

• Nanoparticle Uptake by Human Corneal Cells

  2026-09-15

  Azadi and David systematically examined how PLGA nanoparticle size and surface chemistry influence uptake by human corneal epithelial cells in a mucosa-aware in vitro model. Their results identify energy-dependent endocytosis, especially macropinocytosis and caveolae-mediated uptake, as the dominant mechanisms and provide practical design considerations for topical ocular nanomedicines.

• mRNA-Loaded Dendritic Cells in Resected Melanoma

  2026-09-15

  The reference study evaluated a post-resection strategy using autologous dendritic cells loaded by electroporation with multiple melanoma-antigen mRNAs, alongside scheduled interferon alfa-2b. In 30 patients followed for more than six years, the approach showed manageable treatment-related toxicity and encouraging descriptive overall-survival rates, while its nonrandomized design limits causal interpretation.

• Navitoclax Enhances mTOR Inhibition in PIK3CA CRC

  2026-09-14

  DeStefanis and colleagues identify Navitoclax as a combination partner that enhances PI3K/mTOR-pathway inhibition in PIK3CA-mutant colorectal cancer models. Their organoid screening, in vivo validation, and patient-derived organoid analyses implicate apoptosis induction, BCL-xL dependence, and KRAS-associated resistance as important determinants of response.

• Anlotinib Hydrochloride: Designing Better Assays

  2026-09-14

  Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor whose value extends beyond target potency. This article presents an assay-design framework that connects receptor phosphorylation, ERK signaling, endothelial migration, tube formation, and translational pharmacology.

• Tricine-SDS-PAGE Electrophoresis System Guide

  2026-09-13

  The Tricine-SDS-PAGE Electrophoresis System Gel Preparation Kit is designed to improve separation of small proteins and peptides that are difficult to resolve with conventional Tris-SDS-PAGE. It is intended for research protein electrophoresis, including denaturing and non-denaturing workflows, and must not be used for diagnostic, clinical, or medical testing.

• ABT-263 (Navitoclax): Apoptosis Research Guide

  2026-09-12

  ABT-263, also called Navitoclax, is an orally bioavailable Bcl-2 family inhibitor for mechanistic cancer biology and apoptosis assay workflows. Its strongest research value is the high-affinity disruption of Bcl-2, Bcl-xL, and Bcl-w interactions, with interpretation limited by context-dependent dependence on MCL1 and mitochondrial priming.

• 2-Hydroxypropyl-β-cyclodextrin Workflow Guide

  2026-09-12

  2-Hydroxypropyl-β-cyclodextrin is a water-soluble cyclic oligosaccharide for improving the apparent aqueous solubility of poorly soluble hydrophobic compounds, particularly molecules with aromatic or phenyl groups. It is suitable for pharmaceutical solubility improvement, drug formulation excipient screening, and biochemical formulation workflows, but the available dossier does not establish therapeutic efficacy, safety, pharmacokinetic benefit, or bioavailability.

• Perphenazine: D2 Antagonist Research Guide

  2026-09-11

  Perphenazine is a dopamine D2 receptor antagonist with a broader phenothiazine receptor binding profile. Research data support its use as a benchmark compound for receptor pharmacology, mitochondria-mediated cell death induction, opioid tolerance suppression, and emerging host-directed antibacterial studies.

• Partial Aβ Reduction and Synaptic Transmission

  2026-09-11

  Satir et al. used optical electrophysiology with primary cortical neurons to test whether moderate BACE inhibition can lower amyloid beta secretion without impairing synaptic transmission. Their results support partial, rather than extensive, enzyme inhibition as a potentially safer strategy for preventive Alzheimer’s disease research, while emphasizing that stronger inhibition may disrupt neuronal function.

• SP1–ADAM10–DRP1 Axis in Hypoxic Pulmonary Hypertension

  2026-09-10

  This 2025 study identifies an SP1/ADAM10/DRP1 signaling framework that connects hypoxia-activated endothelial cells with pulmonary artery smooth muscle cells in hypoxia pulmonary hypertension. Its conditioned-medium and inhibitor experiments suggest that endothelial ADAM10 promotes smooth muscle proliferation and survival through DRP1 and PI3K/AKT/mTOR signaling, providing a mechanistic basis for studying intercellular vascular remodeling.

• ABT-737: BCL-2 Protein Inhibitor Guide

  2026-09-10

  ABT-737 is a BH3 mimetic BCL-2 protein inhibitor that targets BCL-2, BCL-xL, and BCL-w to promote intrinsic mitochondrial apoptosis. Preclinical evidence supports apoptosis induction in cancer cells, including lymphoma, multiple myeloma, small-cell lung cancer, and acute myeloid leukemia models.

8052 records 1/537 page Next 12345 下5页 Last page